Moth Erin B, Kiely Belinda E, Martin Andrew, Naganathan Vasi, Della-Fiorentina Stephen, Honeyball Florian, Zielinski Rob, Steer Christopher, Mandaliya Hiren, Ragunathan Abiramy, Blinman Prunella
Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW, Australia; Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW, Australia; Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW, Australia; National Health and Medical Research Council, University of Sydney, Sydney, NSW, Australia.
J Geriatr Oncol. 2020 May;11(4):626-632. doi: 10.1016/j.jgo.2019.07.026. Epub 2019 Aug 19.
Patients with cancer have varied preferences for involvement in decision-making. We sought older adults' preferred and perceived roles in decision-making about palliative chemotherapy; priorities; and information received and desired.
Patients ≥65y who had made a decision about palliative chemotherapy with an oncologist completed a written questionnaire. Preferred and perceived decision-making roles were assessed by the Control Preferences Scale. Wilcoxon rank-sum tests evaluated associations with preferred role. Factors important in decision-making were rated and ranked, and receipt of, and desire for information was described.
Characteristics of the 179 respondents: median age 74y, male (64%), having chemotherapy (83%), vulnerable (Vulnerable Elders Survey-13 score ≥ 3) (52%). Preferred decision-making roles (n = 173) were active in 39%, collaborative in 27%, and passive in 35%. Perceived decision-making roles (n = 172) were active in 42%, collaborative in 22%, and passive in 36% and matched the preferred role for 63% of patients. Associated with preference for an active role: being single/widowed (p = .004, OR = 1.49), having declined chemotherapy (p = .02, OR = 2.00). Ranked most important (n = 159) were "doing everything possible" (30%), "my doctor's recommendation" (26%), "my quality of life" (20%), and "living longer" (15%). A minority expected chemotherapy to cure their cancer (14%). Most had discussed expectations of cure (70%), side effects (88%) and benefits (82%) of chemotherapy. Fewer had received quantitative prognostic information (49%) than desired this information (67%).
Older adults exhibited a range of preferences for involvement in decision-making about palliative chemotherapy. Oncologists should seek patients' decision-making preferences, priorities, and information needs when discussing palliative chemotherapy.
癌症患者在参与决策方面有不同的偏好。我们探寻了老年人在姑息性化疗决策中偏好的和感知到的角色;优先事项;以及所接收和期望获得的信息。
与肿瘤学家就姑息性化疗做出决策的65岁及以上患者完成了一份书面问卷。通过控制偏好量表评估偏好的和感知到的决策角色。Wilcoxon秩和检验评估与偏好角色的关联。对决策中重要的因素进行评分和排序,并描述信息的接收情况和需求。
179名受访者的特征:年龄中位数74岁,男性(64%),正在接受化疗(83%),脆弱(脆弱老年人调查-13评分≥3)(52%)。偏好的决策角色(n = 173)中,积极型占39%,协作型占27%,被动型占35%。感知到的决策角色(n = 172)中,积极型占42%,协作型占22%,被动型占36%,63%的患者其感知角色与偏好角色相符。与偏好积极角色相关的因素:单身/丧偶(p = 0.004,OR = 1.49),拒绝化疗(p = 0.02,OR = 2.00)。排名最重要的(n = 159)是“尽一切可能”(30%),“医生的建议”(26%),“我的生活质量”(20%),以及“活得更长”(15%)。少数人期望化疗治愈他们的癌症(14%)。大多数人讨论了对治愈的期望(70%)、化疗的副作用(88%)和益处(82%)。接受定量预后信息的人(49%)少于期望获得该信息的人(67%)。
老年人在参与姑息性化疗决策方面表现出一系列偏好。肿瘤学家在讨论姑息性化疗时应探寻患者的决策偏好、优先事项和信息需求。